Dec. 11, 2008--Orion Corporation has been informed that an Abbreviated New Drug Application (ANDA) has been filed by Wockhardt Limited with the U.S. FDA seeking authorisation to produce and market generic versions of Stalevo (specifically the 25/200/100; 37.5/200/150 and 50/200/200 mg strengths) in the United States.
The details can be read here.
No comments:
Post a Comment